# Quebec SEAO #20175646

CGH microarrays and laboratory supplies for Santé Québec’s genomic hybridization platform

**Posted:** October 13, 2026
**Respond By:** October 24, 2026
**Identifier:** 20175646
**NAICS:** 325413

Santé Québec is seeking genomic hybridization microarrays and related laboratory supplies for CHU de Québec - Université Laval’s established platform.
- **Buyer:** Santé Québec, through CHU de Québec - Université Laval.
- **Intended supplier and OEM:** **Revvity Health Sciences Canada, inc.** The notice names Revvity as the intended supplier; no actual order quantities are specified.
- **Products requested:**
  - CGX-HD 4plex CGH microarray (GRM 793249).
  - 4plex microarray hybridization kit, capacity for 100 patients (GRM 793250).
  - 4plex microarray DNA labeling kit, capacity for 25 patients (GRM 793251).
  - CGX Oligo aCGH 4plex microarray wash solutions, capacity for 160 patients (GRM 793260).
  - Human Cot-1 DNA for 4plex microarray, capacity for 125 patients (GRM 793261).
  - CGX HD/SNP-100 microarray sealing gasket (GRM 793262).
- **Key technical requirements:** The non-SNP CGH arrays must use a 4x180k format and validated human oligonucleotide design. Products must work with the existing **Agilent SureScan** scanner and Genoglyphix software without adaptations, provide the required genome-wide and clinically significant region resolution, and support detection of more than 200 microdeletion/microduplication regions and over 900 clinically relevant genes.
- **Analysis and support requirements:** Secure remote analysis with activity traceability, automated reporting, and integration with ClinVar, DGV, Decipher, and OMIM. Delivery must provide at least six months of remaining shelf life; frozen products must ship on dry ice. The notice also requires delivery within six weeks, responsive technical support, documentation, ongoing training, and guaranteed Canadian buffer stock.
- **Procurement rationale and notice outcome:** The buyer cites continuity with its established platform and database, traceability, validation, operational risks, and transition risks. The notice invites qualified companies to express interest; a legally admissible, qualified response would lead to a public tender.

### Description

Santé Québec - CHU de Québec - Université Laval is seeking kits and microarrays for its genomic hybridization platform through an intention to enter into a negotiated contract without public tender. The products include CGH microarrays and related hybridization, DNA labeling, washing-solution, Cot-1 DNA, and sealing-gasket supplies. Requirements include compatibility with the Agilent SureScan scanner and Genoglyphix software, specified analytical resolution and detection capabilities, secure remote analysis, reporting and database interoperability, delivery and shelf-life conditions, and supplier support and Canadian inventory. Expressions of interest are due electronically by October 23, 2026; if a qualified, legally admissible expression is received, the organization says it will proceed with a public tender.

[View original listing](https://seao.gouv.qc.ca/avis-resultat-recherche/consulter?ItemId=db134651-dcbc-4e29-9e7e-6adf1dd24b02)